Anis Rehman, MD
Endocrinology, Diabetes & Metabolism · Woodbridge, VANPI 1992146179
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $6,915 of the $8,017 with a category attached, or 86.3%. It is spread thinly across 34 manufacturers, the largest accounting for just 21.6% — the pattern of someone who eats at a lot of different presentations.
Across 273 payments — averaging $29.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$2K
- Lilly USA, LLC$1K
- Novo Nordisk$816
- Insulet Corporation$414
- Bayer$405
- Amgen$381
- plus $3K from 28 others
What the payments were for
- Travel & lodging$1,07413%
- Food & beverage$6,91586%
- Education$280%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 26 | $1,735 |
| Lilly USA, LLC | 58 | $1,402 |
| Novo Nordisk | 27 | $816 |
| Insulet Corporation | 18 | $414 |
| Bayer | 14 | $405 |
| Amgen(2 entities) | 14 | $381 |
| Antares Pharma, Inc. | 9 | $309 |
| BETA Bionics, Inc. | 8 | $307 |
| Abbott | 14 | $301 |
| Dexcom, Inc. | 13 | $289 |
| Xeris Pharmaceuticals, Inc. | 14 | $283 |
| AstraZeneca(2 entities) | 5 | $216 |
| Corcept Therapeutics | 6 | $143 |
| Boehringer Ingelheim | 4 | $111 |
| Sanofi-aventis U.S. LLC | 3 | $107 |
| Amneal Pharmaceuticals LLC | 4 | $102 |
| Acella Pharmaceuticals, LLC | 5 | $100 |
| Ultragenyx Pharmaceutical Inc. | 3 | $61 |
| Recordati_rare_diseases_inc. | 3 | $57 |
| Madrigal Pharmaceuticals | 2 | $51 |
| Tandem Diabetes Care, Inc. | 3 | $49 |
| Merck | 3 | $47 |
| AbbVie | 2 | $40 |
| Cequr Corporation | 2 | $35 |
| Azurity Pharmaceuticals, Inc. | 2 | $35 |
| Pfizer | 2 | $32 |
| Tolmar, Inc. | 2 | $32 |
| Nestle Healthcare Nutrition Inc. | 1 | $28 |
| Sequel Med Tech, LLC | 1 | $25 |
| Avion Pharmaceuticals | 1 | $23 |
| Mannkind Corporation | 1 | $22 |
| Kyowa Kirin, Inc. | 1 | $21 |
| Novartis | 1 | $19 |
| Neurocrine Biosciences, Inc. | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Minimed 670G System$1,074
- iLet Bionic Pancreas$434
- INTELLIS ADAPTIVESTIM$166
- Kerendia$159
- iLet Insulin Infusion Kit Inset$145
- iLet Insulin Infusion Kit Contact Detach$145
- Wegovy$125
- TLANDO$122
- XYOSTED$122
- TEPEZZA$118
- FARXIGA$115
How this compares
$8,017 in reported general payments places this provider in the 80th percentile of 223 endocrinology, diabetes & metabolism providers in Virginia.
See all endocrinology, diabetes & metabolism providers in Virginia →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 205 | $423,156 |
| JardianceEmpagliflozin | 268 | $364,529 |
| TrulicityDulaglutide | 169 | $248,847 |
| FarxigaDapagliflozin Propanediol | 132 | $143,642 |
| MounjaroTirzepatide | 80 | $129,334 |
| RybelsusSemaglutide | 21 | $40,429 |
| Tresiba Flextouch U-100Insulin Degludec | 44 | $37,879 |
| Cinacalcet Hcl | 40 | $31,215 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 11 | $26,013 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 17 | $23,957 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 39 | $21,774 |
| TradjentaLinagliptin | 20 | $21,228 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 116 | $19,654 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 114 | $14,597 |
| Lyumjev Kwikpen U-100Insulin Lispro-Aabc | 11 | $13,702 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $816 | $463,585226 claims |
| Boehringer IngelheimJardiance, Synjardy Xr, Tradjenta, Trijardy Xr | $111 | $420,342319 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $1,402 | $378,181249 claims |
| AstraZenecaFarxiga | $216 | $143,642132 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $102 | $4,642362 claims |
| AbbVieSynthroid | $40 | $3,39344 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 223 endocrinology, diabetes & metabolism providers in Virginia.
Other endocrinology, diabetes & metabolism in Woodbridge
- Farhad ZangenehSterling$1.2M
- James MulindaRoanoke$788K
- Jeffrey SicatGlen Allen$657K
- Dewey BaileyRoanoke$645K
- Domenica RubinoArlington$608K
- Samamtha HudsonMidlothian$372K
- Elias SirajNorfolk$316K
- Allen BurrisPowhatan$261K
- Samim EnayatFairfax$217K
- Denise ArmelliniFairfax$152K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.